Fortress Biotech Inc. (FBIO) is an innovative biomedical company committed to identifying, in-licensing, and developing high-potential, marketed biopharmaceutical products and drug candidates. Founded in 2013 and based in New York, USA, the company is listed on the NASDAQ stock exchange under the ticker symbol “FBIO”.
The company's core competencies lie in the fields of dermatology, oncology, rare diseases, and gene therapy. Through its partner and subsidiary companies, FBIO aims to foster the development of a diverse portfolio that includes both commercial-stage products and developmental-stage drug candidates, which are backed by robust clinical development plans.
One of Fortress Biotech’s strategic business models involves creating and managing subsidiary companies, each of which is focused on a specific disease or segment. Subsidiaries of Fortress Biotech include Avenue Therapeutics, Checkpoint Therapeutics, Caelum Biosciences, and Helocyte, among others. This model allows the company to effectively allocate resources across multiple product development opportunities while limiting risk.
FBIO is known to work with top-tier pharmaceutical companies and research institutions. They have relationships with key opinion leaders and leading clinicians in their respective therapeutic areas. These relationships strengthen the company’s product development and contribute to their overall strategy.
One of FIBO's significant achievements was obtaining FDA approval for its dermatology products, such as Triderm®, Targadox®, and Exelderm®, which became commercially available under the Journey Medical Corporation, a subsidiary of FBIO.
The company stands at a forefront of innovation and is anticipated to reshape the therapeutic landscape with its forward-thinking approach to healthcare. FBIO boasts of a well-distinguished management team guided by strong leadership, which includes veterans with vast experiences in the biotech and pharmaceutical industries.
At its core, Fortress Biotech’s strategy focuses on acquiring promising assets and allocating resources for their advancement. Relying on sophisticated technical evaluation and commercial intelligence, the company is propelling innovations that may significantly improve patients’ lives.
Epitomizing resilience, Fortress Biotech Inc continues to navigate the challenging world of drug discovery and development, attempting to build value while insulating shareholders from as much risk as possible. The strategic diversity provided by the company’s numerous subsidiaries ensures that, collectively, the group is incredibly active across the full spectrum of research and development, as well as commercialization avenues. This gives Fortress Biotech a key advantage as it pushes forward in its mission to provide transformative therapies for patients in need.